Intellia Therapeutics Inc Investor Event Transcript
Good morning, and welcome to Intellia Therapeutics' Investor Event. My name is Drew, and I will be your conference operator today. Please be advised that this call is being recorded at the company's request. (Operator Instructions) I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you, operator, and good morning, everyone. I'm pleased to welcome you to Intellia's Investor event, featuring updated interim data from the Phase I/II clinical trial of NTLA-2002.
On Saturday, Intellia issued a press release detailing these results, which were presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, also known as ACAAI, held this past week in Louisville, Kentucky. This release, along with the accompanying presentation, can be found in the investors and media convention of Intellia's website At intelliatx.com. As a reminder,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |